Billing for VeriStratÆ

VeriStratÆ is a new blood test that will help determine if a patient is likely to benefit from a specific lung cancer therapy. It is reported to stratify patients with advanced non-small cell lung cancer into good or poor outcome categories after treatment with epidermal growth factor receptor tyrosine kinase inhibitors (e.g., gefitinib, erlotinib). VeriStratÆ consists of serum mass spectrometry, followed by computer processing or algorithmic analysis of the spectra to generate a patient-specific report. Providers should bill Medicare for VeriStratÆ using the following CPT code: • 83789©: Mass spectrometry quant. • If this test is billed with an unspecified CPT code such as 84999, payment will be based on the payment amount for CPT code 83789. Source: TrailBlazer Health Enterprises, Medicare Part A and Part B MAC for Jurisdiction 14; comprised of Colorado, New Mexico, Oklahoma and Texas.